BI-SGC @EC2609A

Sinopharm subsidiary to participate in Chinese Grains & Oils Congress 2026.

Sinopharm Group subsidiary Sinopharm Accord announces board resolutions approving headquarters restructuring and subsidiary cancellation

Hang Seng Index quarterly review results expected to be announced after market close today.

Nomura cuts Sinopharm Group price target to HK$25.09, maintains Buy rating

Hong Kong Budget supports innovation, boosting sentiment in the healthcare sector.

JPMorgan recently increased its stake in Sinopharm Group, drawing attention to institutional positioning.

Analysts are bullish on Sinopharm's profit recovery, highlighting partnerships with AstraZeneca and Betta Pharmaceuticals.

Subsidiaries of Sinopharm Group involved in recent pricing and metering complaints.

Upcoming 'Two Sessions' in China to Focus on Pharma Distribution and Procurement Policies

China Pharmaceutical Market Projected to Reach $573 Billion by 2033

Sinopharm Group sees large block trade sell-off; stock shows technical breakout patterns.

GSK's Linerixibat Granted Priority Review in China

German Chancellor's visit to China continues; focus on healthcare cooperation.

MSCI China Index quarterly rebalancing to take effect after market close on February 27.

Hang Seng Index quarterly review adjustments will take effect on March 9.

Sinopharm Subsidiary Receives Approval for Human Albumin Batch

Stock Code Alert: Sinopharm Group is 01099.HK; 2591.HK refers to a different security.

Market analysis maintains 'Strong Buy' rating for Sinopharm Group.

Market assesses potential impact of EU tech ban on Chinese biopharma supply chains.

Sinopharm shares break 60-day MA; market eyes momentum at next open.

CCOE

STARCOIN GROUP

ONEFORCE HLDGS

ROYAL DELUXE

STELUX HOLDINGS

TE HEALTHCARE

ASIAPAC FIN INV

WELIFE TECH

DRINDA

TIMELESS

600511

00322

159736

01099

The Hang Seng Index closed at 26,765 points, up 175 points or 0.7%; the Hang Seng TECH Index reported 5,260 points, down 10 points or 0.2%. The total market turnover was HKD 236.765 billion. Among the actively traded blue-chip stocks, HAIDILAO rose over 6%, HSBC HOLDINGS, TINGYI, SINOPHARM, TIME INTERCON, and WANGUO GOLD GP all reached new highs

AASTOCKS

SINOPHARM(CNCM LTD)

TINGYI

Tianhong CSI Food and Beverage ETF

China Merchants Guozheng Food and Beverage ETF

Huaan CSI SWS Food and Beverage ETF

ChinaAMC CSI Food & Beverage Sub-Industry ETF

HSBC HOLDINGS

SINOPHARM

Hang Seng TECH Index

TIME INTERCON

Hang Seng Index

Sinopharm Accord

WANGUO GOLD GP

HAIDILAO

The Hong Kong Index closed at 26,765 points, up 175 points; the Hang Seng TECH Index closed at 5,260 points, down 10 points. HAIDILAO rose over 6%. HSBC HOLDINGS, TINGYI, SINOPHARM, TIME INTERCON, and WANGUO GOLD GP reached new highs with active trading

03115

510150

03033

The Hang Seng Index closed at 26,789 points, up 199 points or 0.8%; the Hang Seng Tech Index reported 5,288 points, up 17 points or 0.3%. The China Enterprises Index rose 81 points or 0.9%, closing at 9,088 points. Among the actively traded blue-chip stocks, Meituan, Ping An, Tencent, and Alibaba all saw increases, with Haidilao rising more than 5%. Li Ning, Sinopharm, CHINA RES MIXC, Hengan, and MTR all reached new highs

ISHARESHSI

China Merchants SSE Consumer 80 ETF

CSOP HS TECH

LI NING

CHINA RES MIXC

Hang Seng TECH ETF I

Huatai-PB CSOP Hang Seng Technology ETF(QDII)

HSTECH ETF

PING AN

ChinaAMC Hang Seng Technology ETF(QDII)

Dacheng Hang Seng Technology ETF(QDII)

TENCENT

MEITUAN

The Half-Day Report: The Hang Seng Index closed at 26,789 points, up 199 points; the Hang Seng Tech Index closed at 5,288 points, up 17 points. HAIDILAO rose over 5%, LI NING, SINOPHARM, CHINA RES MIXC, Hengan, and MTR reached new highs

516500

516820

512010

Sinopharm Group Co. Ltd. (HKG:1099) has a low P/E ratio of 8.4x, indicating potential investor caution due to declining earnings. The company's EPS fell by 14% last year and 11% over three years, leading to a forecasted growth of only 14% next year, below the market's 20%. This suggests that investors are not optimistic about future earnings, resulting in a low P/E. Analysts believe the share price may not rise significantly in the near future, and there is one warning sign to consider before investing.

Simplywall

ChinaAMC CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Guotai SSE STAR Brand Name Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

ICBCCS SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Universal 800 Health Care ETF

E Fund Hang Seng SCHK Innovative Drug ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng Health Care ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Sinopharm Group Co. Ltd.'s (HKG:1099) Low P/E No Reason For Excitement

03320

Beijing launched a pilot program for online diagnosis and treatment services on January 31, starting with three pediatric subspecialties at Beijing Children's Hospital and Capital Institute of Pediatrics. This service provides online pre-consultation, online diagnosis and treatment, and medication delivery for first-time patients, aiming to ensure the safety and quality of diagnosis and treatment. Doctors can complete the initial diagnosis and issue prescriptions via the internet

Wallstreetcn

CHINARES PHARMA

ChinaAMC CSI All Share Health Care Devices ETF

Shanghai Pharma

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ALI HEALTH

JD HEALTH

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

PA GOODDOCTOR

Founder Fubon CSI Medicine and Medical Device Innovation ETF

GF CSI All Share Health Care ETF

SH PHARMA

Dacheng CSI All Share Health Care Equipment and Services ETF

This afternoon, appointment reservations opened for the pilot program of internet diagnosis and treatment in Beijing

Sinopharm Group Co. Ltd. has filed an updated list of directors with the Hong Kong Stock Exchange, detailing their roles and committee memberships. The board includes Non-Executive, Executive, and Independent Non-Executive Directors, with Jin Bin as Chairman. The filing reflects a broad distribution of responsibilities across governance, strategy, compliance, remuneration, and nomination functions. This information was published by Sinopharm Group via the Hong Kong Stock Exchange's Issuer Information Service.

Reuters

Sinopharm Group Files Director List with HKEX

Sinopharm Group's renewed distribution partnership with Shanghai Henlius Biotech extends their collaboration until 2028. Despite a modest recent share price increase, Sinopharm's long-term returns remain strong. The company's current price-to-earnings ratio of 8.1x suggests undervaluation compared to industry averages. However, a DCF model indicates a fair value of HK$15.36, suggesting potential overvaluation. Risks include policy changes and slower procurement growth. Investors are encouraged to explore further investment opportunities and assess potential mispricing in the market.

Sinopharm Group (SEHK:1099): Valuation Check After Renewing Shanghai Henlius Distribution Partnership

Sinopharm Group Co. Ltd. will hold an extraordinary general meeting on December 19, 2025, in Shanghai, China. Shareholders will vote on appointing Mr. Jin Bin and Ms. Li Ying as non-executive Directors of the Board, with authorization for the Board to determine their remuneration and service contracts. This announcement was published by Sinopharm Group via the Hong Kong Stock Exchange's Issuer Information Service.

Sinopharm Group Co. Ltd. Announces Date for Extraordinary General Meeting

02696

Shanghai Henlius Biotech Inc. has renewed its distribution agreement with Sinopharm Group, signing a new framework on December 3, 2025. This extends their partnership, with transactions conducted in the ordinary course of business. An Independent Board Committee will advise shareholders on the agreement's fairness. The news was generated by Public Technologies using AI and is for informational purposes only.

HENLIUS

Shanghai Henlius Biotech Renews Distribution Agreement with Sinopharm

SINOPHARM announced that due to work arrangements, Zhao Bingxiang has resigned from his positions as non-executive director and chairman of the board on November 28. The board has resolved to elect Jin Bin as the chairman and authorized representative, and on the same day appointed Jin Bin and Li Ying as non-executive directors

SINOPHARM appoints chairman

Sinopharm Group Co. Ltd. announced the resignations of Mr. Zhao Bingxiang and Ms. Feng Rongli from various board and committee positions, effective upon their replacements' appointment at the company's general meeting.

marketscreener

Sinopharm Group Co. Ltd. Announces Board and Committee Resignations

Sinopharm Group Co. Ltd. announced the resignation of Mr. Zhao Bingxiang as non-executive director, chairman of the board, and authorized representative due to work arrangements. The company will provide details on new director appointments in a future circular to shareholders. This announcement was made via the Hong Kong Stock Exchange's Issuer Information Service.

Sinopharm Chairman Zhao Bingxiang Resigns Amid Board Reshuffle

JPMorgan Chase & Co's short position in H-shares of Sinopharm Group decreased to 1.45% on Nov 21 - HKEX

JPMorgan Chase